These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 29978469

  • 1. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL, Kim HP, Cho YW, Min DW, Cheon SK, Lim YJ, Song SH, Kim SJ, Han SW, Park KJ, Kim TY.
    Int J Cancer; 2019 Jan 15; 144(2):389-401. PubMed ID: 29978469
    [Abstract] [Full Text] [Related]

  • 2. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG.
    Clin Cancer Res; 2016 Feb 01; 22(3):644-56. PubMed ID: 26224873
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH.
    BMC Cancer; 2016 Jul 26; 16():531. PubMed ID: 27461218
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 8. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
    Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab RB, Wong A, John-Baptiste A, Bagrodia S, Los G, Bender S, Christensen J, Vanarsdale T.
    PLoS One; 2013 Sep 01; 8(6):e67258. PubMed ID: 23826249
    [Abstract] [Full Text] [Related]

  • 9. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
    Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU.
    Oncogene; 2016 Sep 29; 35(39):5119-31. PubMed ID: 26999641
    [Abstract] [Full Text] [Related]

  • 10. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF, Cho S, Liang X, Park S, Jin K, Chen Q, Pan D, Zahnow CA, Rein AR, Sukumar S.
    Mol Oncol; 2017 May 29; 11(5):552-566. PubMed ID: 28296140
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.
    Gynecol Oncol; 2019 Apr 29; 153(1):158-164. PubMed ID: 30630630
    [Abstract] [Full Text] [Related]

  • 13. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE, Yang L, Chen K, Wang Y, Liu YR, Pan SL, Gaur S, Hu S, Yen Y.
    Oncotarget; 2015 May 10; 6(13):11061-73. PubMed ID: 25857298
    [Abstract] [Full Text] [Related]

  • 14. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S, Mukherji D, Shamseddine A.
    Int J Mol Sci; 2015 Sep 23; 16(9):22976-88. PubMed ID: 26404261
    [Abstract] [Full Text] [Related]

  • 15. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
    Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, Chen Z, dos Santos O, Ayral-Kaloustian S, Venkatesan A, Hollander I.
    Clin Cancer Res; 2011 May 15; 17(10):3193-203. PubMed ID: 21325073
    [Abstract] [Full Text] [Related]

  • 16. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Gazi M, Moharram SA, Marhäll A, Kazi JU.
    Cancer Lett; 2017 Apr 28; 392():9-16. PubMed ID: 28159681
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 28; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL, Ma WJ, Chen S, Wu XZ, Zhang HR, Zhang JH.
    Zhonghua Zhong Liu Za Zhi; 2016 Aug 28; 38(8):578-88. PubMed ID: 27531477
    [Abstract] [Full Text] [Related]

  • 20. Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling.
    Kang DW, Lee BH, Suh YA, Choi YS, Jang SJ, Kim YM, Choi KY, Min DS.
    Clin Cancer Res; 2017 Dec 01; 23(23):7340-7350. PubMed ID: 28939743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.